|
DE69332987T2
(de)
*
|
1992-04-02 |
2004-05-19 |
Smithkline Beecham Corp. |
Verbindungen verwendbar für die Behandlung von Allergien und Entzündungskrankheiten
|
|
AU7174794A
(en)
*
|
1993-06-18 |
1995-01-17 |
Smithkline Beecham Corporation |
Compounds
|
|
US5780667A
(en)
*
|
1993-10-01 |
1998-07-14 |
Smithkline Beecham Corporation |
Compounds, compositions and treatment of allergies and inflammation therewith
|
|
US6013827A
(en)
*
|
1994-03-11 |
2000-01-11 |
Smithkline Beecham Corporation |
Compounds
|
|
GB9404706D0
(en)
*
|
1994-03-11 |
1994-04-27 |
Smithkline Beecham Corp |
Compounds
|
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
|
JPH10511395A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
1,3,3−(三置換)シクロヘキサン単量体および関連する化合物
|
|
JPH10511390A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
1,4,4−(三置換)シクロヘクス−1−エンダイマーおよび関連化合物
|
|
JPH10511391A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
3,3−(二置換)シクロヘキサン−1−オール二量体および関連化合物
|
|
HUT77350A
(hu)
*
|
1994-12-23 |
1998-03-30 |
Smithkline Beecham Corporation |
4,4-(diszubsztituált)-1-ciklohexanol-származékok és az ezeket tartalmazó gyógyszerkészítmények
|
|
JPH10511389A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
4,4−(二置換)シクロヘキサン−1−オール二量体および関連化合物
|
|
ZA9510826B
(en)
*
|
1994-12-23 |
1996-06-20 |
Smithkline Beecham Corp |
3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
|
|
ATE230404T1
(de)
*
|
1995-05-18 |
2003-01-15 |
Altana Pharma Ag |
Cyclohexyldihydrobenzofurane
|
|
DE59610077D1
(de)
*
|
1995-05-18 |
2003-02-27 |
Altana Pharma Ag |
Phenyldihydrobenzofurane
|
|
AR004471A1
(es)
*
|
1995-05-31 |
1998-12-16 |
Smithkline Beecham Corp |
Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
US5891883A
(en)
*
|
1995-12-21 |
1999-04-06 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
|
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
|
US6288261B1
(en)
|
1998-12-18 |
2001-09-11 |
Abbott Laboratories |
Inhibitors of matrix metalloproteinases
|
|
DZ3019A1
(fr)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
|
|
US20020077276A1
(en)
*
|
1999-04-27 |
2002-06-20 |
Fredeking Terry M. |
Compositions and methods for treating hemorrhagic virus infections and other disorders
|
|
US20040220424A1
(en)
*
|
1999-08-06 |
2004-11-04 |
Smithkline Beecham Corporation |
Process for preparing acids via alpha-chloroepoxy esters
|
|
UY26268A1
(es)
*
|
1999-08-06 |
2001-01-31 |
Smithkline Beecham Corp |
Procedimiento para preparar acidos a traves de alfa-cloroep xi- esteres ley 17164 art 127
|
|
PT1212089E
(pt)
|
1999-08-21 |
2006-08-31 |
Altana Pharma Ag |
Combinacao sinergica de roflumilast e salmeterol
|
|
US6572794B1
(en)
|
2000-07-24 |
2003-06-03 |
Essilor International Compagnie Generale D'optique |
Method of manufacturing a photochromic molded article
|
|
FR2816950B1
(fr)
|
2000-11-17 |
2003-02-14 |
Essilor Int |
Procede d'obtention d'un latex photochromique
|
|
FR2819258B1
(fr)
|
2001-01-11 |
2003-04-11 |
Essilor Int |
Procede d'obtention d'un latex photochromique stabilise, latex obtenu et application a l'optique ophtalmique
|
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
US20040136991A1
(en)
|
2002-07-19 |
2004-07-15 |
Abbott Biotechnology Ltd. |
Treatment of anemia using TNFalpha inhibitors
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
KR20050115331A
(ko)
|
2003-04-01 |
2005-12-07 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
불임증 포스포디에스터라제의 억제제
|
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
|
JPWO2005037269A1
(ja)
*
|
2003-10-21 |
2006-12-28 |
住友製薬株式会社 |
新規ピペリジン誘導体
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
EP1885397A4
(en)
|
2005-05-16 |
2010-01-20 |
Abbott Biotech Ltd |
USE OF A TNF HEMMER FOR THE TREATMENT OF EROSIVE POLYARTHRITIS
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
EP1957530A2
(en)
|
2005-10-21 |
2008-08-20 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
DK1948235T3
(da)
|
2005-11-01 |
2013-11-25 |
Abbvie Biotechnology Ltd |
Fremgangsmåder til bestemmelse af effektiviteten af adalimumab hos patienter med Bechterews sygdom med CTX-II og MMP3 som biomarkører
|
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EP2738178A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
EP2013211B1
(en)
|
2006-04-21 |
2012-03-14 |
Novartis AG |
Purine derivatives for use as adenosin a2a receptor agonists
|
|
TWI527603B
(zh)
|
2006-06-30 |
2016-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
|
MX2009003185A
(es)
|
2006-09-29 |
2009-04-03 |
Novartis Ag |
Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
|
|
BRPI0718266A2
(pt)
|
2006-10-30 |
2014-01-07 |
Novartis Ag |
Compostos heterocíclicos como agentes anti-inflamatórios.
|
|
CA2673803A1
(en)
|
2007-01-10 |
2008-07-17 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
|
JP2010523695A
(ja)
*
|
2007-04-11 |
2010-07-15 |
アルコン リサーチ, リミテッド |
アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのTNFαのインヒビターおよび抗ヒスタミン薬の使用
|
|
ATE499363T1
(de)
|
2007-05-07 |
2011-03-15 |
Novartis Ag |
Organische verbindungen
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US8034782B2
(en)
|
2008-07-16 |
2011-10-11 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
ES2559319T3
(es)
|
2007-06-04 |
2016-02-11 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
|
NZ585789A
(en)
|
2007-12-10 |
2012-03-30 |
Novartis Ag |
Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
|
|
WO2009087224A1
(en)
|
2008-01-11 |
2009-07-16 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
MX2010013675A
(es)
|
2008-06-10 |
2011-02-15 |
Novartis Ag |
Derivados de pirazina como bloqueadores del canal de sodio epitelial.
|
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
|
BRPI1012162A2
(pt)
|
2009-04-29 |
2016-01-12 |
Abbott Biotech Ltd |
dispositivo de injeção automática
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EP2464649A1
(en)
|
2009-08-12 |
2012-06-20 |
Novartis AG |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
ES2709108T3
(es)
|
2009-08-17 |
2019-04-15 |
Intellikine Llc |
Compuestos heterocíclicos y usos de los mismos
|
|
BR112012008061A2
(pt)
|
2009-08-20 |
2016-03-01 |
Novartis Ag |
compostos de oxima heterocíclica
|
|
EP2482798A1
(en)
*
|
2009-10-01 |
2012-08-08 |
Alcon Research, Ltd. |
Olopatadine compositions and uses thereof
|
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
|
CA2781725A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
US20120014956A1
(en)
|
2010-02-02 |
2012-01-19 |
Hartmut Kupper |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
RU2695703C2
(ru)
|
2010-04-21 |
2019-07-25 |
Эббви Байотекнолоджи Лтд. |
Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов
|
|
US20110287018A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
|
CN103079594B
(zh)
|
2010-06-03 |
2016-04-13 |
艾伯维生物技术有限公司 |
用于治疗化脓性汗腺炎(hs)的用途和组合物
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
CA2825316C
(en)
|
2011-01-24 |
2020-05-05 |
Abbvie Biotechnology Ltd. |
Automatic injection devices having overmolded gripping surfaces
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
AU2012220572A1
(en)
|
2011-02-25 |
2013-08-29 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
CN103764672A
(zh)
|
2011-03-01 |
2014-04-30 |
辛纳吉制药公司 |
制备鸟苷酸环化酶c激动剂的方法
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
|
WO2013038362A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
|
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
N−置換ヘテロシクリルカルボキサミド類
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
CN104363914A
(zh)
|
2011-11-23 |
2015-02-18 |
因特利凯有限责任公司 |
使用mTOR抑制剂的增强的治疗方案
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
JP2015512425A
(ja)
|
2012-04-03 |
2015-04-27 |
ノバルティス アーゲー |
チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
|
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
JP6499591B2
(ja)
|
2013-02-25 |
2019-04-10 |
シナジー ファーマシューティカルズ インコーポレイテッド |
結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
|
JP6694385B2
(ja)
|
2013-08-09 |
2020-05-13 |
アーデリクス,インコーポレーテッド |
リン酸塩輸送阻害のための化合物及び方法
|
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
|
EP3134396B1
(en)
|
2014-04-24 |
2019-09-18 |
Novartis AG |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
EP3145951A1
(en)
|
2014-06-24 |
2017-03-29 |
InSight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
WO2016016822A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
|
WO2020048828A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Pharma Aktiengesellschaft |
5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
|
|
WO2020048827A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Aktiengesellschaft |
1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
|
|
EP3972599B1
(en)
|
2019-05-21 |
2025-10-22 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|
|
EP3980121A1
(en)
|
2019-06-10 |
2022-04-13 |
Novartis AG |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
|
AU2020338971B2
(en)
|
2019-08-28 |
2023-11-23 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
|
WO2023208941A1
(en)
|
2022-04-26 |
2023-11-02 |
Essilor International |
Photochromic optical article having a mirror coating
|